AX1 has launched Console 2.0, a platform on the Base blockchain that lets AI agents perform tasks and get paid in USDC using the x402 payment standard by Coinbase. This new version simplifies setup, allowing users to deploy AI agents quickly to work onchain and compete for weekly rewards paid in tokenized SpaceX stock. Console 2.0 has already processed over 430,000 x402 payments from nearly 5,000 agents, ranking it among the top apps on Base. Upcoming features include more partner quests and direct agent competitions, expanding the agent economy ecosystem AX1 is building.
AX1's launch of Console 2.0 is the subject, with Pluang's Technology-sector market snapshot as of Oct 23, 2026 20:02 WIB: out of 150 priced US tech stocks, 34 rose and 108 fell. Notable movers include STM at USD 43.28 with a 1-day change of -1.84%, STX at USD 631.01 down 1.73%, and AMPL at USD 16.77 down 1.73%. The most notable figure is STM's 100% buy order activity on Pluang.
The global generator cooling systems market is projected to grow from $3.76 billion in 2026 to $5.03 billion by 2031 at a CAGR of 6.0%. Growth is fueled by rising demand for reliable backup and continuous power in expanding data centers, industrial f...
The global computed tomography (CT) market is undergoing significant innovation driven by photon-counting technology, AI integration, mobile imaging, and point-of-care applications. These advancements are enhancing image quality, workflow efficiency,...
Global zinc supply is expected to fall short by 88,000 tonnes in 2026 amid declining mine production, while tin demand is projected to outpace supply growth through 2035. This has renewed exploration in historic polymetallic mining districts in the U...
Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...
Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in precl...
